FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics
Rhea-AI Summary
FibroBiologics (Nasdaq:FBLG) filed a new provisional patent application with the USPTO for oral fibroblast and fibroblast-derived therapeutics. The platform targets delivery to the gastrointestinal tract using encapsulation materials, hydrogels, nanoparticles, protective layers, and pH-sensitive coatings to preserve viability and enable targeted release.
The application covers whole fibroblast cells, spheroids, extracellular vesicles, fragments, conditioned media, and genetically modified variants, with potential use in chronic GI disorders such as inflammatory bowel disease, irritable bowel syndrome, Crohn's disease, ulcerative colitis, peptic ulcer disease, celiac disease, gastritis, and gastrointestinal cancers.
Positive
- None.
Negative
- None.
News Market Reaction – FBLG
In the May 18 session, FBLG gained 3.81%, reflecting a moderate positive market reaction. Argus tracked a peak move of +4.7% during that session. Argus tracked a trough of -7.1% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 11 | Pipeline expansion | Positive | -14.7% | Expanded fibroblast platform into Hantavirus pulmonary syndrome preclinical work. |
| May 05 | Shareholder letter | Positive | -3.6% | Outlined CYWC628 trial start, timelines, and broader preclinical program plans. |
| May 04 | Preclinical data | Positive | -3.6% | Reported burn-wound fibroblast spheroid data with anti-inflammatory biomarker shifts. |
| May 04 | Clinical supply ready | Positive | -5.5% | Released first cGMP CYWC628 batch enabling Phase 1/2 DFU trial enrollment. |
| Apr 30 | Earnings update | Positive | +10.6% | Q1 2026 results with CYWC628 manufacturing progress and capital raise details. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent FBLG news has often been followed by negative price reactions even on seemingly constructive R&D or pipeline updates, with only the Q1 results posting a positive move.
Over the last few weeks, FibroBiologics has reported multiple fibroblast-focused milestones, including Q1 2026 results on Apr 30, cGMP CYWC628 drug release and burn-wound preclinical data on May 4, a CEO shareholder letter on May 5, and a Hantavirus program update on May 11. Most of these scientific and clinical-progress announcements coincided with share price declines, while the Q1 update was the only event with a positive +10.61% 24-hour reaction. Today’s patent filing fits into this continuing R&D expansion narrative.
Key Terms
provisional patent application regulatory
u.s. patent and trademark office regulatory
extracellular vesicles medical
enteric coatings medical
hydrogels medical
nanoparticles technical
gastrointestinal tract medical
pH-sensitive technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOUSTON, May 18, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending focused on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the filing of a new provisional patent application with the U.S. Patent and Trademark Office (USPTO) titled “Oral Fibroblasts and Fibroblast-Derived Therapeutics and Delivery Systems for Same” covering oral delivery systems designed to protect fibroblast-based therapeutics through the stomach and enable targeted release in the gastrointestinal tract.
The provisional patent application describes an oral administration platform intended to deliver fibroblasts and fibroblast-derived therapeutics, including whole cells, spheroids, extracellular vesicles, fragments, conditioned media, and genetically modified variants, to the GI tract using encapsulation materials and enteric coatings engineered to preserve viability and bioactivity during transit.
The disclosed platform contemplates multilayer delivery architectures incorporating hydrogels, nanoparticles, protective intermediate layers, and pH-sensitive outer coatings designed to bypass gastric acid and digestive enzymes before releasing therapeutic payloads in targeted regions of the intestine. The application describes potential oral administration modality across chronic gastrointestinal disorders including inflammatory bowel disease, irritable bowel syndrome, peptic ulcer disease, celiac disease, gastritis, Crohn's disease, ulcerative colitis, and gastrointestinal cancers.
Pete O'Heeron, Founder and Chief Executive Officer of FibroBiologics commented, "A successful oral fibroblast therapeutic could meaningfully change the treatment paradigm by offering a more accessible, non-invasive approach designed to deliver regenerative and immunomodulatory activity directly to the gastrointestinal tract. We believe this oral platform has the potential to open an entirely new frontier for fibroblast-based medicine."
"What makes this filing especially compelling is the breadth of the therapeutic architecture," said Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics. "The application covers not only fibroblasts, but also fibroblast-derived materials, engineered variants, multilayer encapsulation approaches, and programmable release concepts intended to maintain viability and function through oral delivery. From a scientific perspective, this gives us a versatile framework for exploring how fibroblast-based therapeutics may help restore barrier function, modulate inflammation, and support tissue repair in gastrointestinal disease settings."
For more information, please visit FibroBiologics' website, email FibroBiologics at info@fibrobiologics.com or follow FibroBiologics on LinkedIn, YouTube, Facebook or X.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.
Cautionary Statement Regarding Forward-Looking Statements
This communication contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the scope and strength of the Company’s intellectual property portfolio, the potential of FibroBiologics’ novel fibroblast technology, and the potential indications for FibroBiologics’ programs. These forward-looking statements are based on FibroBiologics’ management’s current expectations, estimates, projections, and beliefs, as well as a number of assumptions concerning future events. When used in this communication, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics’ management’s control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption “Risk Factors” and elsewhere in FibroBiologics’ annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC’s website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics’ liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of FibroBiologics’ R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
